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                                   1. Introduction
   Mammalian oocytes are surrounded by several layers of cells and grow in ovarian folli-
cles: inner layers of granulosa cells are separated from blood vessels and theca cells by a 
vasement membrane lining the follicle. Periodical secretion of pituitary gonadotropins such as 
follicle stimulating hormone (FSH) and leuteinizing hormone (LH) induces oocyte maturation 
and, after ovulation of matured oocytes, ovarian follicles undergo profound changes in mor-
phology and physiologic properties. Theca interna cells and granulosa cells transform into 
small and large luteal cells, respectively 1) and blood vessels invade the luteinizing granulosa 
cell layers to nourish cells, giving rise to corpora lutea ultimately (Fig. 1) . Although a large 
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       Fig.1: An endocrine relationship between pituitary gland and ovarian follicles. FSH 
             stimulates the maturation of ovarian follicles. Ovulation induced by LH is a 
            signal for granulosa cells to transform to luteal cells and form the corpus 
             luteum. Gonadotropins from pituitary gland such as FSH and LH stimulates 
             feedback regulation by estradiol, inhibin, and progesterone.
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number of follicles are present in a given ovary, only a limited number of follicles are 
selected and prevailed to further respond to the pituitaly gonadotropins during a given cycle. 
The way of this selection has been a puzzle for a long time. selected and prevailed to further 
respond to the pituitary gonadotropins during a given cycle. 
    Ovarian granulosa cells have attracted profound attentions in various points for past 
several decades; in particular, they show dramatic transformation to luteal cells in coupled 
with ovulation and they play essential roles in oocyte development and maturation 2-5). Granu-
losa cells from mammalian species can be cultured in vitro in media containing serum 6) or 
occasionally in serum-free media 7-9) and, under appropriate conditions, granulosa cells re-
tain the ability of progesterone synthesis and luteinization, making this system attractive for 
not a few cell biologists 6.9-13) 
    Granulosa cells can be classified into three groups based on their locations inside the 
follcile 16). The mural granulosa cells are localized next to basement lamina and are presumed 
to be most active in various functional aspects. Closer to the antral cavity are the antral gra-
nulosa cells, and finally granulosa cells surrounding the oocyte are called cumulus cells. 
Although these three groups of granulosa cells are derived from common precursor cells in 
the process of ovary formation, they are diverged enough to respond differently to various 
stimuli. Besides this stratified structure of granulosa cells, each granulosa cell, cumulus 
cells and oocytes are connected each other through "gap junctions" 15-19); this structure enables 
the transportation of metabolites such as nucleotides 19) , sugars 20) , amino acids, small pep-
tides 21.22) and low molecular weight substances such as cAMP and Ins (1,4 ,5)P3  23.24) 
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                 Figure 2: Granulosa cells as a model for hormonal target cell 
    Ovarian follicles were used to be speculated simply as being regulated by gonadotropins 
directly, that is "endocrine control". Recently, however, it becomes clear that the develop-
ment and maturation of ovarian follicles can't be fully achieved without controls carried out 
in "paracrine or autocrine" fashion through granulosa cells (Fig. 2) . This review will focus 
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on signaling pathways unique to granulosa cells with the aim of understanding the events in 
ovarian follicles at the molecular level. 
                           2. Steriodhormones and steroidogenesis 
   Steroid hormones play key roles in the development and maturation of ovarian folicles. 
Granulosa cells and luteal cells produce and secrete two major ovarian steroid hormones:es-
tradiol and progesterone. Estradiol, together with FSH, induces FSH receptors on granulosa 
cells  14) and also the secretion of gonadotropin releasing hormone (GnRH) at hypothalamus 
which causes the subsequent release of LH from the pituitary25.26)Under the continuous pre-
sence of LH, granulosa cells become luteal cells after ovulation which secrets some estradiol, 
but its predominant secretion is progesterone. Progesterone is known to have an activity to 
inhibit follicle maturation, thereby these cells prevent more follicles to mature. 
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                        Figure 3: "Two cell, two gonadotropin theory" 
   In contrast to progesterone whose synthesis is completed within granulosa cells or luteal 
cells, estradiol requires another cells, theca cells, to go through its synthesis, which has 
been refered to "two cell, two gonadotropin theory" 27'28 (Fig.3) ; a cascade reaction (Fig.4) 
starts by synthesizing androstenedione in thecal cells in which process 17 a -hydroxysteroid 
dehydrogenase (generally abbreviated as HSD) plays key role and its activity is repressed by 
LH surge 29. Androstenedione is then transfered into granulosa cells through basal membrane 
and is converted to estradiol by P450 aromatase whose activity has been shown to be reg-
ulated by FSH 9.29,30) 
   Progesterone is produced within granulosa cells and luteal cells (Fig.4) . The side-chain 
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        Figure 4: Production of steroid hormone on ovarianfollicles. HSD: Hydroxysteroid 
             dehydrogenase is abbreviated. 
cleavage of cholesterol is the first and the rate-limiting step in progesterone biosynthesis and 
this conversion from cholesterol to pregnenolone is catalyzed by mitochondrial enzymes: con-
sisting of the cytochrome P450scc and it's ancillary electron transport proteins, adrenodoxin 
and adrenodoxin reductase 31,32) These enzyme activities have been found to be regulated by 
gonadotropins at transcription level 33-37) 
   Gonadotropins transduce these signals through transmembrane receptors (described 
below) to which G-proteins are coupled 38-40) In fact, it is known that ganadotropin induces 
intracellular cAMP 41-44) and that chemicals such as forskolin, 8-boromo-cAMP, dibutyryl ade-
nosine 3' , 5'-monophosphatase induce three mitochondrial genes, p450scc , adrenodoxin, and 
adrenodoxin reductase 33-37,45) , resulting in the production of progesterone 46-48i . On the other 
hand, after luteinization by the administration of LH or human chorionic gonadotropin (hCG) 
, the activity of mitochondrial scc system is maintained by cAMP-independent mechanism 
29,34.49.50) to compensate the constitutive synthesis of large quantity of progesterone in corpora 
lutea. The regulatory mechanisms of progesterone synthesis, therefore, are defferent be-
tween granulosa cells and luteal cells. 
   cAMP is believed to function through cAMP dependent protein kinase (A-kinase) which 
is composed of two catalytic subunits (C a and C i9) and two regulatory subunits (RI and 
RII) The RII subunit is induced in granulosa cells by FSH and estradiol at transcription 
level si.sz> It may also be regulated by LH; the expression of RII mRNA significantly increases 
in granulosa cells till LH surge and decreases dramatically after LH surge. Since estradiol 
and forkolin 29) can induce the mRNA, cAMP is assumed to regulate the expression of the RII 
( 379 )
                         Molecular Biology of the Ovarian Follicle 
gene. On the other hand, only minor changes have been observed in RI and C a subunit  29)  .
This regulatory mechanism of the RII subunit contributes to keep catalytic subunits under the 
tight control of the R subunit and cAMP, so that follicles can be maintained at synchronized 
state in cAMP-mediated events such as ovulation and luteinization which occur only in resp-
once to the LH surge and significant increase of intracellular cAMP concentration 29). 
                                    3. Receptors 
FSH receptors: The expression of the FSH receptor has been examined mainly by binding 
activity in vitro and in vivo 53.54) The activity appears first in granulosa cells around the 
primary follicle stage 19.54.55) at which oocytes complete the growing, and the hormone activity 
increases during prepubertal development 56) . The expression of the FSH receptor is reported 
to be regulated by estradiol in association wiht FSH in vivo 54.57) but not by estradiol alone 5a.58)_ 
   Through an estrous cycle, FSH binding capacity remains fairly constant with minor fluc-
tuations compared to the LH binding capacity 59'66),and the numbers of FSH receptors decline 
as follicles mature (in porcine) and ovulate (in human; dominant folicle) 61) . Although the 
regulatory mechanism of this reduction of FSH receptors is unclear yet, progesterone which 
is secreted in the process of luteinization is presumed to play a role, at least in porcine in 
vitro system 67). Further , down regulation of FSH receptors on granulosa cell surface has also 
been observed by exposing cells continuously to FSH in vitro "5 ; this may have a role to 
progress the cycle by regulating responsiveness to FSH. 
   A cDNA clone of the FSH receptor has been isolated from rat sertoli cells 65) and the re-
ceptor molecule has been predicted to be highly related to the TSH receptor 66) and the LH re-
ceptor 39) which belong to a family of G protein coupled receptors. In fact, it is well known 
that FSH treatment of granulosa cells increases intracellular cAMP concentration. Further, 
by using the isolated cDNA clone as a probe, the expression of FSH receptor mRNA was ex-
amined 67); a limited expression of the FSH receptor mRNA was detected in granulosa cells in 
small follicles and the copy number substantially increased after pregnant mare serum gona-
dotropin (PMSG) stimulation. The expression of FSH receptor was declined by further treat-
ment of human chorionic gnadotropin (hCG) , and this might correspond to a phenomenon 
observed in vivo; the FSH receptor mRNA declines after preovulatory LH surge. 
LH receptors: The LH receptor is a G protein-coupled transmembrane receptor as described 
and increases intracellular cAMP concentration upon LH stimulation as expected. LH recep-
tors are known to be induced by FSH in vivo 54) and in vitro 68.69) These findings are consis-
tent with the reports that LH receptors can be detected only in granulosa cells from large 
preovulatory follicles 59.55.70) and that, in contrast, granulosa cells isolated from immature 
hypophysectamized and estrogen-treated rats showed little LH/hCG binding activity 14). 
   Quite a few growth factors or hormones have been identified as effectors of the express-
ion of LH receptors. Among them, platelet derived growth factor (PDGF) 71) , insulin like 
growth factor 1 (IGF-1) 72'79) , insulin 73.74) , estradiol 54.69.75) progesterone 69) and androgens fis) 
are known to induce LH receptors in association with FSH. On the other hand, epidermal 
growth factor (EGF) 71'76) , basic fibroblast growth factor (bFGF) 71•77) and glucocorticoids 76) 
antagonize FSH. 
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    How does each effector regulate the expression is not clear yet. However, the possible 
involvement of cAMP has been proposed by the observation that its analogs (8-Br-cAMP, 
dbcAMP)48.80-82)or inducing agents 80.84) of cAMP (cholera toxin, prostaglandin E2, forskolin) 
could stimulate the expression of functional LH receptors. Synthetic analogs of cAMP gener-
ally induced less LH receptors than physiological dose of FSH, suggesting that cAMP inde-
pendent mechanism, in addition to cAMP dependent mechanism, might be involved in the in-
duction of LH receptors " . With regard this, the commitment of C kinase in the pathway has 
been implicated '85). 
   In contrast to the FSH receptor mRNA which is confined to granulosa cells, LH receptor 
mRNA can be detected widely in theca cells, granulosa cells and corpora lutea 67'. Moreover, 
multiple sizes of the LH/CG receptor transcript were detected in gonadal cells, although the 
significance of this observation has not been elucidated yet 86-89) 
Other receptors: In addition to gonadotropin receptors, receptors for several other effectors 
have been reproted to be present in granulosa cells and luteal cells. Prolactin (PRL) is 
known to be an important luteotropic agent and to inhibit the induction of 20 a -hydrox-
ysteroid dehydrogenase (20 a -HSD) which catalyzes the conversion of active progesterone to 
less active 20 a -dihydroprogesterone, resulting in the acumulation of progestorone in serum 
which is essential for maintenance of pregnancy and fetal well being 9°.91).Although immature 
granulosa cells has few prolactin binding sites prior to stimulation with FSH14,92) ,fully 
grown granulosa cells in large follicles and luteal cells in corpora lutea have a signifucant 
amount of specific PRL binding sites '939'. In fact, it was reported that an exposure to ex-
ogenous FSH induce PRL receptors in granulosa cells in vivo 2,92) and in vitro 92'85). This induc-
tion of PRL receptors by FSH is also cAMP dependent, because cAMP analogs 83) and cholera 
toxin 95' can mimic the induction by FSH. Once induced, the continued presence of FSH, LH 
or hCG is required to maintain the PRL receptor level 95' . With this regard, it is proposed 
that Lh/hCG and PRL influence the binding capacity each other positively 14). 
   GnRH, whose primary target site is the pituitary glands to sitmulate hormonal secretion, 
has been proposed, surprisingly, to have binding site on granulosa cells and play a role for 
follicular maturation as well. GnRH inhibits the induction of progestrone synthesis by FSH in 
granulosa cells and luteal cells 9'8), and also inhibits the induction of LH and PRL receptors 
in vitro 97,98) , thereby GnRH seems to have an activity as an antagonist of FSH. On the other 
hand, a treatment of granulosa cells with GnRH alone can stimulate steroidgenesis 99,100> fol-
licular maturation 101) and ovulation b02,103) 
                                4. Non-Steroidal regulators 
Growth Factors: Several peptide growth factors have been identified as essential regulators 
for the development and maturation of ovarian follicles. Among them, EGF and bFGF are 
known to have negative effects for follicular maturation:e.g. , they suppress the effect of the 
induction of LH receptors in cultured granulosa cells 71'76'7' . Generally speaking, ligands 
which increase intracellular cAMP concentration promote the maturation and enhance the 
synthesis of LH receptors, PRL receptors, progesterone and estradiol. In contrast, ligands 
which reduce intracellular cAMP concentration repress the maturation. However, both EGF 
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and bFGF may exert their inhibitory effect, not only by repressing cAMP formation or re-
ducing cAMP concentration  76.77.104> but by activating the calcium and phospholipid dependent 
protein kinase C 105) 
   EGF causes the reduction of estradiol biosynthesis 14) , while it stimulates progesterone 
synthesis 106) indicating that the estradiol and progesterone synthesis are regulated through 
distinct mechanisms 14) . bFGF, on the other hand, inhibits both progesterone synthesis 107) 
and estradiol synthesis in bovine granulosa cells 106.109) Since estradiol is important for ova-
rian follicular maturation, EGF and bFGF may regulate follicular maturation by reducing 
both estradiol synthesis and the LH receptor level in granulosa cells. 
   The induction of receptors for EGF and bFGF are shown to be regulated by gonadotro-
pins; FSH treatment induces the binding sites for both EGF and bFGF in cultured rat granu- 
losa cells without changing their binding affinities110,111)while LH/hCG reduces the binding 
sites for EGF. Likewise, treatment with cAMP-inducing agents which mimic FSH function 
such as 8-bromo-cAMP, forskolin, and choleragen stimulte EGF receptor expression, where-
as GnRH or 12-0-tetradecanoyl-phorbol 13-acatate (TPA) which antagonize FSH reduce the 
expression of the EGF receptors 110) The induction of EGF and bFGF receptors by FSH im-
ply the presence of autoregulation mechanism for the follicular maturation; FSH promotes fol-
licular maturation, while EGF and bFGF antagonize FSH functions. 
   PDGF, another peptide growth factor, in known to be secreted by platelet during clot 
formation and therefore, this growth factor has been proposed to have a role during folliculer 
rupture and subsequent formation of the corpus hemorrhagicum 71) In contrast to the inhibi-
tory activities of EGF and bFGF, PDGF has been shown to enhance the FSH stimulation of 
intracellular cAMP production, steroidogenesis, and LH receptors '1.76,112) . PDGF exerts its 
effect by maintaining FSH-sensitive adenylate cyclase and reducing phosophodiesterase activ-
ity 76) 
   Recent studies on insulin-like growth factors (IGFs) and its binding proteins (IGFBPs) 
have revealed regulatory systems in ovaries. Two kinds of IGF, IGF-1 and IGF-2, and six 
kinds of IGFBP have been identified in serum and other body fluid including ovarian follicu-
lar fluid 113-115). IGF-1/IGF-1 receptor system is also shown to be produced in ovarian granu-
losa cells and induced by FSH 11fi-118>. IGF-1, like insulin, is known to promote FSH-mediated 
differentiation of granulosa cells and induce cAMP production, steroidogenesis, LH receptor 
and inhibin 72,73,119-121) . Therefore, FSH and IGF-1 synergize to further stimulate follicular 
maturation. IGF-1, however, at the same time, stimulates the expression of IGFBPs which 
antagonize FSH and IGF-1, implying the presence of a feedback mechanism among these 
three factors. IGF-2 mRNA, in the other hand, is detected in cultured human granulosa cells 
and inducible by FSH and hCG 122), the role of IGF-2 in follicles is not yet clear though. 
   IGFBP-2 and IGFBP-3 are reported to be repressed by FSH, a derivatives of cAMP and 
8-Br cAMP 123) . IGFBP-3 is also regulated by prostaglandin E2 and F2 a in luteinized granulo-
sa cells 1'4). IGFBP-4 and 5 have a role to reduce the production of estradiol and progester-
one 125) and the expression of IGFBP-4 and 5 is regulated by FSH, which negatively controls 
at transcription level and also stimulates the production of a protease for degradation of 
IGFBP-4 and 5 125) 
   Transforming growth factor- de (TGF- ) has been reported to be produced in murine 
corpora lutea and to mediate luteotropic action of PRL 126) . TGF- Q has also been identified 
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in cultured rat granulosa cells and found to increase both basal and FSH-stimulated inhibin 
a and i3 A-subinit mRNA level 127) Furthermore, TGF- a inhibits forskolin-induced 17 a 
-hydroxysteorid dehydrogenase activity and androstenedione production in bovine thecal cells 
28) , thereby TGF- plays a role in ovarian follicles. 
Meiosis Arresting Factor (MAF) : Mammalian follicular fluid has been reported to contain 
an activity capable of preventing spontaneous dissolution of germinal vesicle (GVBD) of 
oocytes and similar activities have been reported to be secreted by granulosa cells 3,128) 
Oocyte maturation inhibitor (OMI) , one of such inhibitor of GVBD 129) , has been isolated 
from porcine follicular fluid and shown to be a heat-stable peptide with wide species specifici-
ties 129) . Another factor, which has been speculated to be secreted by granulosa cells and 
localized at cell surface, has been identified by Sato et al 2) and called meiosis arresting factor 
(MAF) . 
Mtillerian inhibitory factor (MIF) is also known as an inhibitory factor and is detected 
in both follicular fluid and garanulosa cells by immunohistochemical research 130-132) Although 
the ways these factors affect on the resumption of meiotic arrest are still unclear, they may 
exert their activities by regulating intracellular cAMP concentration of oocytes, because only 
the declining of cAMP concentration has been consistent phenomenon associated with the re-
sumption of meiosis 133'13") 
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                Figure 5: Inhibin, activin, and'follistatin as endocrine regulators 
Inhibin and activin: An administraion of steroid hormones to gonad induces the secretion of 
water-soluble proteins, known as inhibin and activin, which regulate the hypotha-
lamo-hypophysial system. Inhibin has an activity to suppress the synthesis and secretion of 
FSH /3 -subunit selectively at pituitary 135-138) (Fig. 5) The growth and proliferation of granu-
losa cells are thus regulated through such feedback mechanism by FSH and inhibin. 
   Two forms of inhibins have been purified from porcine follicular fluid 139), each form is a 
heterodimer comprised of common a -subunit and a distinct j3 -subunit, that is, j3 A or /3 
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B-subunit. The former one, a  P A, is called inhibin A and the latter one, a /3 B, is called 
inhibin B. 13 A and f3 B subunits share 70% similarity each other in their primary structures 
and much less similarity is present between a and /1140) 
   In the ovary, the a -subunit mRNA is expressed always much more abundantly than the 
13 -subunit mRNA 143.144) because the inhibin a -subunit is expressed not only in the granulo-
sa cells but in thecal cells and ovarian stroma, while the inhibin 13 A-subunit is expressed 
only in granulosa cells in maturating follicles 145) . The cellular content of mRNA coding for 
each subunit is regulated by variety of factors. PMSG was reported to increase the express-
ion of the inhibin a and / subunit 141) and FSH, LH and TGF- P 1 were found to have the 
same activities in cultured rat granulosa cells 127.142) EGF, bFGF and GnRH, on the other 
hand, which are known to suppress granulosa cell maturation (LH receptor expression 
steroidogenesis, and so on) repress the expression of the a and 13 A subunits 127) . IGF-I 
and PRL have no significant effect on inhibin expression. Forskolin can mimic FSH and in-
creases the inhibin subunit mRNA level 127) , indicating the involvement of signaling pathway 
via cAMP dependent protein kinase (s) . 
   The dimerization of the inhibin /3 A- and /3 B-subunits gives rise to the three formes of 
activin: A (/3 A- P A) , B (/ B- /3 B) , and AB (13 A- /3 B) 139,146-148) Although activin A 147) 
and AB 148) have been purified, activin B has not been isolated nor fully characterized yet. 
Interestingly, despite of sharing common l3 -subunit, biological activities of activin are oppo-
site to that of inhibin. As this [3 -subunit has similarity with TGF- /3 149) , which also posses-
ses FSH-releasing activity 150) , activin and inhibin are classified as members of TGF- /3 
family. 
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            Figure 6: Inhibin, activin, and TGF-/3 , as autocrine/paracrine regulators 
   Both inhibin and activin function mostly in endocrine fashion, but it is also known that 
these factors exert their effects in autocrine or paracrine manner as well. Inhibin, for 
example, has been reported to repress the biosynthesis of estradiol in granulosa cells through 
the inhibition of P450aromatase activity 12) and to augment progesterone secretion in cultured 
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granulosa cells 152,146) whereas activin has been shown to enhance P450aromatse activity and 
inhibit progesterone synthesis146,151.152)On the other hand, TGF- 13 has dual activities; it en-
hances both P450aromatse activity and progesterone synthesis 151-153) Futhermore. activin in-
creases both basal and FSH-stimulated expression of inhibin in cultured rat granulosa cells, 
while inhibin has no effect on activin expression 154) . These relationships are summarized 
schematically in Figure 6. 
   Proteins capable of binding to inhibin and activin have been identified in serum and ova-
rian follicular fluid. Follistatin in follicular fluid is one of such proteins 155,156) and follistatin 
inhibits pituitary release of FSH146,156)Follistatin is reported to be expressed in the same tis-
sue where activin and inhibin are expressed '57-160) Another inhibin/activin binding protein, 
a 2M, has been identified in human serum. Although a 2M can bind to both activin and 
inhibin, it has no effect on the biological activities of inhibin and activin as far as tested 156) 
                            5. Seaching for Stage-Specific Genes 
   As described above, a variety of growth factors or substances have been revealed to 
play important roles in the process of development and maturation of ovarian follicles. It is 
getting clearer that these ligands exert their signals ultimately by regulating the expression of 
essential genes either positively or negatively. Therefore, an identification of a group of such 
genes may be crucial to understand the follicular development and maturaion at the molecular 
level. Tanaka et al. constructed cDNA libraries from porcine granulosa cells as well as cor-
pus luteum, and identified a group of stage- and tissue-specific genes by differential screen-
ing. Among clones so far characterized, the clone TS543, which was found to be expressed 
preferentially at early and functional stages of the corpus luteum by Northern blot analysis 
161) (Fig.7A) , turned out to encode a counterpart of human collagenase inhibitor 162) by DNA 
sequence analysis. The product was localized in the capsule of corpus luteum as well as in 
the connective tissue around blood vessels (Fig. 7B) . Tissue inhibitor of metalloproteinase 
(TIMP) , including the collagenase inhibitor, are proposed to be induced by LH or steroid 
hormone 163.164) and the enzyme activities or mRNA can be detected in fully matured follicular 
fluid 164) or in corpus luteum 165) . Taken together, it seems likely that TIMP including col-
lagenase inhibitor regulates metalloproteinae activity upon luteinization, ovulation, or corpus 
luteum formation. In fact, it is proposed that the apical collagenous matrix of the preovula-
tory follicle may decrease partly due to proteolytic enzymes such as the metalloproteinase 
163,166,167) In addition, plasminogen activator is reported to be synthesized in granulosa cells 
111,268) and to play a role in ovulation b69) 
   Three other cDNA clones specific to the corpus luteum have been characterized so far 
(Fig. 7A, panel b, c, d, and e) , and two of them were found to encode mitochondrial genes 
(to be published elsewhere) . Since mitochondria play essential roles in the process of 
luteinization and in the maintenance of corpus luteum as described above, characterization of 
these gene products will reveal important aspects of luteinization. 
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 Figure 7B:In situ hybridization for collagenase inhibitor. An ovary at functional stage was used.
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                                         6. Conclusions 
      Many investigators have used granulosa cells as a model system to understand cellular 
   transformation as well as steroidogenesis. However, there still exist many interesting ques-
   tions to be resolved in this field; e.g. , the way of oocyte maturation is regulated by granulo-
   sa cells in a manner of intercellular responses, the identification of genes that trigger 
   luteinization and meiotic resumption and so on. Making use of established granulosa cell lines 
   may be useful to this end  170,171) (T. Tanaka, unpublished) . 
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